トリプルネガティブ乳癌 (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "トリプルネガティブ乳癌" in Japanese language version.

refsWebsite

Global rank Japanese rank

4^th place

24^th place

2^nd place

6^th place

5^th place

19^th place

3clinicaltrials.gov

5,225^th place

low place

304^th place

20^th place

1semanticscholar.org

11^th place

1,537^th place

1uchicagomedicine.org

low place

low place

low place

low place

610^th place

915^th place

low place

8,165^th place

1tokushima-u.ac.jp

low place

5,097^th place

1cancernetwork.com

low place

low place

1cancerjournal.net

low place

low place

447^th place

1,043^rd place

1voiceofcancerpatients.com

low place

low place

1,684^th place

6,245^th place

719^th place

3,311^th place

1medpagetoday.com

9,274^th place

low place

low place

low place

low place

low place

1medicalxpress.com

8,255^th place

low place

low place

low place

14^th place

320^th place

222^nd place

498^th place

archive.today

“Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization”. Cancer 112 (5): 995-1000. (March 2008). doi:10.1002/cncr.23226. PMID 18098228. オリジナルの2013-01-05時点におけるアーカイブ。.

cancer.gov

Reynolds, Sharon (2007年7月24日). “Spotlight: Triple-Negative Breast Cancer Disproportionately Affects African American and Hispanic Women”. National Cancer Institute. 2008年10月13日閲覧。

cancerit.jp

“トリネガ乳がんにおける5種類の分子サブタイプの解明”. 海外がん医療情報リファレンス (2018年4月24日). 2021年5月27日閲覧。

cancerjournal.net

Kok, Victor (2018). “Hepatic metastasectomy and paclitaxel provide long-term survival for a young woman with recurrent triple-negative metastatic breast cancer: 16 years follow-up”. Journal of Cancer Research and Therapeutics 14 (3): 722-723. doi:10.4103/0973-1482.179087.

cancernetwork.com

“Understanding and treating triple-negative breast cancer”. Oncology 22 (11): 1233-1239; discussion 1239–40, 1243. (October 2008). PMC 2868264. PMID 18980022.

celldex.com

Burris (2009年). “A Phase I/II Study of CR011-vcMMAE (CDX-011), an Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Breast Cancer”. 2021年5月27日閲覧。

clinicaltrials.gov

“A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer”. 2021年5月27日閲覧。
臨床試験番号 NCT01997333 研究名 "Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (METRIC)" - ClinicalTrials.gov
“Study of Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC”. 2021年5月27日閲覧。

cytodyn.com

First Patient in CytoDyn's Triple-Negative Metastatic Breast Cancer Trial Shows Significant Reduction in Circulating Tumor Cells (CTC) and Reduced Tumor Size

doi.org

“Triple-negative breast cancer”. The New England Journal of Medicine 363 (20): 1938-1948. (November 2010). doi:10.1056/Nejmra1001389. PMID 21067385.
“Triple-negative breast cancer: an unmet medical need”. The Oncologist 16 Suppl 1: 1–11. (2011). doi:10.1634/theoncologist.2011-S1-01. PMID 21278435.
“Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?”. BMC Cancer 11: 299. (July 2011). doi:10.1186/1471-2407-11-299. PMC 3151231. PMID 21762477.
“Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype”. Clinical Cancer Research 14 (5): 1368-1376. (March 2008). doi:10.1158/1078-0432.CCR-07-1658. PMID 18316557.
Pruss D, Morris B, Hughes E, Eggington JM, Esterling L, Robinson BS, van Kan A, Fernandes PH, Roa BB, Gutin A, Wenstrup RJ, Bowles KR (August 2014). “Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes”. Breast Cancer Research and Treatment 147 (1): 119-132. doi:10.1007/s10549-014-3065-9. PMID 25085752.
Stevens, Kristen N.; Vachon, Celine M.; Couch, Fergus J. (2013). “Genetic Susceptibility to Triple-Negative Breast Cancer”. Cancer Research 73 (7): 2025–2030. doi:10.1158/0008-5472.CAN-12-1699.
Lehmann, Brian D.; Bauer, Joshua A.; Chen, Xi; Sanders, Melinda E.; Chakravarthy, A. Bapsi; Shyr, Yu; Pietenpol, Jennifer A. (2011-07-01). “Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies” (英語). Journal of Clinical Investigation 121 (7): 2750–2767. doi:10.1172/JCI45014. ISSN 0021-9738. PMC 3127435. PMID 21633166.
Bareche, Y.; Venet, D.; Ignatiadis, M.; Aftimos, P.; Piccart, M.; Rothe, F.; Sotiriou, C. (2018-04). “Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis” (英語). Annals of Oncology 29 (4): 895-902. doi:10.1093/annonc/mdy024. PMC 5913636. PMID 29365031.
“Identification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data”. Oncotarget 7 (44): 71620–71634. (November 2016). doi:10.18632/oncotarget.12287. PMC 5342106. PMID 27690302.
Kok, Victor (2018). “Hepatic metastasectomy and paclitaxel provide long-term survival for a young woman with recurrent triple-negative metastatic breast cancer: 16 years follow-up”. Journal of Cancer Research and Therapeutics 14 (3): 722-723. doi:10.4103/0973-1482.179087.
“Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis”. PLOS Medicine 13 (12): e1002193. (December 2016). doi:10.1371/journal.pmed.1002193. PMC 5154510. PMID 27959926.
“Risk factors for triple-negative breast cancer in women under the age of 45 years”. Cancer Epidemiology, Biomarkers & Prevention 18 (4): 1157-1166. (April 2009). doi:10.1158/1055-9965.EPI-08-1005. PMC 2754710. PMID 19336554.
“PARP inhibitors stumble in breast cancer”. Nature Biotechnology 29 (5): 373-374. (May 2011). doi:10.1038/nbt0511-373. PMID 21552220.
小川洋二「肺癌におけるFDG-PET/CT―有用性と診断上の注意点―」『肺癌』第50巻第6号、日本肺癌学会、2010年、853-859頁、doi:10.2482/haigan.50.853、ISSN 0386-9628、NAID 130000414531。
“Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization”. Cancer 112 (5): 995-1000. (March 2008). doi:10.1002/cncr.23226. PMID 18098228. オリジナルの2013-01-05時点におけるアーカイブ。.
“Metformin in breast cancer: time for action”. Journal of Clinical Oncology 27 (20): 3271-3273. (July 2009). doi:10.1200/JCO.2009.22.1630. PMID 19487373.
“GSTP1 Is a Driver of Triple-Negative Breast Cancer Cell Metabolism and Pathogenicity”. Cell Chemical Biology 23 (5): 567–578. (May 2016). doi:10.1016/j.chembiol.2016.03.017. PMC 4876719. PMID 27185638.

elsevier.com

linkinghub.elsevier.com

Bareche, Y.; Venet, D.; Ignatiadis, M.; Aftimos, P.; Piccart, M.; Rothe, F.; Sotiriou, C. (2018-04). “Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis” (英語). Annals of Oncology 29 (4): 895-902. doi:10.1093/annonc/mdy024. PMC 5913636. PMID 29365031.

fda.gov

Commissioner, Office of the (2020年4月22日). “FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments” (英語). FDA. 2020年11月19日閲覧。

jci.org

Lehmann, Brian D.; Bauer, Joshua A.; Chen, Xi; Sanders, Melinda E.; Chakravarthy, A. Bapsi; Shyr, Yu; Pietenpol, Jennifer A. (2011-07-01). “Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies” (英語). Journal of Clinical Investigation 121 (7): 2750–2767. doi:10.1172/JCI45014. ISSN 0021-9738. PMC 3127435. PMID 21633166.

medicalxpress.com

Finally, targeted therapies for triple-negative breast cancer. June 2016

medpagetoday.com

"SABCS: PARP Inhibitor Data Called 'Spectacular' "; Dec 2009

medscape.com

Chustecka, Zosia (2007年3月19日). “Survival Disadvantage Seen for Triple-Negative Breast Cancer”. Medscape Medical News. 2008年10月13日閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

“Triple-negative breast cancer”. The New England Journal of Medicine 363 (20): 1938-1948. (November 2010). doi:10.1056/Nejmra1001389. PMID 21067385.
“Triple-negative breast cancer: an unmet medical need”. The Oncologist 16 Suppl 1: 1–11. (2011). doi:10.1634/theoncologist.2011-S1-01. PMID 21278435.
“Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?”. BMC Cancer 11: 299. (July 2011). doi:10.1186/1471-2407-11-299. PMC 3151231. PMID 21762477.
“Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype”. Clinical Cancer Research 14 (5): 1368-1376. (March 2008). doi:10.1158/1078-0432.CCR-07-1658. PMID 18316557.
Pruss D, Morris B, Hughes E, Eggington JM, Esterling L, Robinson BS, van Kan A, Fernandes PH, Roa BB, Gutin A, Wenstrup RJ, Bowles KR (August 2014). “Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes”. Breast Cancer Research and Treatment 147 (1): 119-132. doi:10.1007/s10549-014-3065-9. PMID 25085752.
Lehmann, Brian D.; Bauer, Joshua A.; Chen, Xi; Sanders, Melinda E.; Chakravarthy, A. Bapsi; Shyr, Yu; Pietenpol, Jennifer A. (2011-07-01). “Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies” (英語). Journal of Clinical Investigation 121 (7): 2750–2767. doi:10.1172/JCI45014. ISSN 0021-9738. PMC 3127435. PMID 21633166.
Bareche, Y.; Venet, D.; Ignatiadis, M.; Aftimos, P.; Piccart, M.; Rothe, F.; Sotiriou, C. (2018-04). “Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis” (英語). Annals of Oncology 29 (4): 895-902. doi:10.1093/annonc/mdy024. PMC 5913636. PMID 29365031.
“Understanding and treating triple-negative breast cancer”. Oncology 22 (11): 1233-1239; discussion 1239–40, 1243. (October 2008). PMC 2868264. PMID 18980022.
“Identification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data”. Oncotarget 7 (44): 71620–71634. (November 2016). doi:10.18632/oncotarget.12287. PMC 5342106. PMID 27690302.
“Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis”. PLOS Medicine 13 (12): e1002193. (December 2016). doi:10.1371/journal.pmed.1002193. PMC 5154510. PMID 27959926.
“Risk factors for triple-negative breast cancer in women under the age of 45 years”. Cancer Epidemiology, Biomarkers & Prevention 18 (4): 1157-1166. (April 2009). doi:10.1158/1055-9965.EPI-08-1005. PMC 2754710. PMID 19336554.
“PARP inhibitors stumble in breast cancer”. Nature Biotechnology 29 (5): 373-374. (May 2011). doi:10.1038/nbt0511-373. PMID 21552220.
“Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization”. Cancer 112 (5): 995-1000. (March 2008). doi:10.1002/cncr.23226. PMID 18098228. オリジナルの2013-01-05時点におけるアーカイブ。.
“Metformin in breast cancer: time for action”. Journal of Clinical Oncology 27 (20): 3271-3273. (July 2009). doi:10.1200/JCO.2009.22.1630. PMID 19487373.
“GSTP1 Is a Driver of Triple-Negative Breast Cancer Cell Metabolism and Pathogenicity”. Cell Chemical Biology 23 (5): 567–578. (May 2016). doi:10.1016/j.chembiol.2016.03.017. PMC 4876719. PMID 27185638.

ncbi.nlm.nih.gov

“Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?”. BMC Cancer 11: 299. (July 2011). doi:10.1186/1471-2407-11-299. PMC 3151231. PMID 21762477.
Lehmann, Brian D.; Bauer, Joshua A.; Chen, Xi; Sanders, Melinda E.; Chakravarthy, A. Bapsi; Shyr, Yu; Pietenpol, Jennifer A. (2011-07-01). “Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies” (英語). Journal of Clinical Investigation 121 (7): 2750–2767. doi:10.1172/JCI45014. ISSN 0021-9738. PMC 3127435. PMID 21633166.
Bareche, Y.; Venet, D.; Ignatiadis, M.; Aftimos, P.; Piccart, M.; Rothe, F.; Sotiriou, C. (2018-04). “Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis” (英語). Annals of Oncology 29 (4): 895-902. doi:10.1093/annonc/mdy024. PMC 5913636. PMID 29365031.
“Understanding and treating triple-negative breast cancer”. Oncology 22 (11): 1233-1239; discussion 1239–40, 1243. (October 2008). PMC 2868264. PMID 18980022.
“Identification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data”. Oncotarget 7 (44): 71620–71634. (November 2016). doi:10.18632/oncotarget.12287. PMC 5342106. PMID 27690302.
“Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis”. PLOS Medicine 13 (12): e1002193. (December 2016). doi:10.1371/journal.pmed.1002193. PMC 5154510. PMID 27959926.
“Risk factors for triple-negative breast cancer in women under the age of 45 years”. Cancer Epidemiology, Biomarkers & Prevention 18 (4): 1157-1166. (April 2009). doi:10.1158/1055-9965.EPI-08-1005. PMC 2754710. PMID 19336554.
“GSTP1 Is a Driver of Triple-Negative Breast Cancer Cell Metabolism and Pathogenicity”. Cell Chemical Biology 23 (5): 567–578. (May 2016). doi:10.1016/j.chembiol.2016.03.017. PMC 4876719. PMID 27185638.

nii.ac.jp

ci.nii.ac.jp

坂東良美「トリプルネガティブ乳癌の多様性と病理診断 : 基底細胞タイプとは」『四国医学雑誌』第76巻第5-6号、徳島医学会、2020年12月、259-266頁、ISSN 0037-3699、NAID 120006979183。
小川洋二「肺癌におけるFDG-PET/CT―有用性と診断上の注意点―」『肺癌』第50巻第6号、日本肺癌学会、2010年、853-859頁、doi:10.2482/haigan.50.853、ISSN 0386-9628、NAID 130000414531。

semanticscholar.org

“Triple-negative breast cancer”. The New England Journal of Medicine 363 (20): 1938-1948. (November 2010). doi:10.1056/Nejmra1001389. PMID 21067385.

tokushima-u.ac.jp

repo.lib.tokushima-u.ac.jp

坂東良美「トリプルネガティブ乳癌の多様性と病理診断 : 基底細胞タイプとは」『四国医学雑誌』第76巻第5-6号、徳島医学会、2020年12月、259-266頁、ISSN 0037-3699、NAID 120006979183。

uchicagomedicine.org

“Old drugs bring new hope to triple negative breast cancer - UChicago Medicine” (英語). www.uchicagomedicine.org. 2019年5月7日閲覧。

voiceofcancerpatients.com

Voice of Cancer Patients an online cancer patients community

wikipedia.org

en.wikipedia.org

臨床試験番号 NCT01997333 研究名 "Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (METRIC)" - ClinicalTrials.gov

wiley.com

www3.interscience.wiley.com

“Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization”. Cancer 112 (5): 995-1000. (March 2008). doi:10.1002/cncr.23226. PMID 18098228. オリジナルの2013-01-05時点におけるアーカイブ。.

worldcat.org

search.worldcat.org

Lehmann, Brian D.; Bauer, Joshua A.; Chen, Xi; Sanders, Melinda E.; Chakravarthy, A. Bapsi; Shyr, Yu; Pietenpol, Jennifer A. (2011-07-01). “Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies” (英語). Journal of Clinical Investigation 121 (7): 2750–2767. doi:10.1172/JCI45014. ISSN 0021-9738. PMC 3127435. PMID 21633166.
坂東良美「トリプルネガティブ乳癌の多様性と病理診断 : 基底細胞タイプとは」『四国医学雑誌』第76巻第5-6号、徳島医学会、2020年12月、259-266頁、ISSN 0037-3699、NAID 120006979183。
小川洋二「肺癌におけるFDG-PET/CT―有用性と診断上の注意点―」『肺癌』第50巻第6号、日本肺癌学会、2010年、853-859頁、doi:10.2482/haigan.50.853、ISSN 0386-9628、NAID 130000414531。